Metoject Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a cofactor in DNA, RNA and protein synthesis. By limiting these building blocks, the drug reduces proliferation of rapidly dividing cells such as activated immune cells and cancer cells.

The dose of methotrexate is individualized. A qualified prescriber determines the appropriate amount, frequency and duration based on the specific indication, patient weight, renal and hepatic function, and response to therapy. No standard dose is provided here.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of a high risk of fetal malformations and miscarriage. Breastfeeding is also not recommended, as the drug can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the Metoject Pen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

The primary alternative is oral methotrexate, which offers similar pharmacologic activity but may have variable absorption and higher gastrointestinal side effects. Subcutaneous delivery via Metoject Pen provides more consistent bioavailability, often allowing lower doses and potentially fewer GI adverse events, while maintaining the same therapeutic effects.

Metoject Pen should be stored refrigerated at 2‑8 °C. Keep the device in its original packaging, protect it from light, and avoid freezing or shaking. If a temporary excursion above this temperature occurs, use the product within the time frame specified in the label.

The pen is a pre‑filled, single‑use device designed for subcutaneous injection. After confirming the correct dose, the user removes the safety cap, selects the injection site (typically the abdomen or thigh), and presses the activation button to deliver the medication. Disposal follows local sharps‑waste regulations.

Serious risks include severe liver toxicity, pulmonary fibrosis or interstitial pneumonitis, profound bone‑marrow suppression leading to pancytopenia, acute renal failure, life‑threatening infections, and anaphylactic reactions. Patients should report symptoms such as persistent jaundice, unexplained shortness of breath, fever, or unusual bruising promptly.

Metoject Pen is contraindicated in pregnant women, individuals with severe hepatic impairment, uncontrolled renal failure, active serious infections, and those with known hypersensitivity to methotrexate or any excipients. Caution is also advised for patients with a history of lung disease or alcohol misuse.